Enliven Therapeutics, Inc. (ELVN)
NMS · Healthcare · Biotechnology
$54.32
-3.40%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$3.98B
Shares Outstanding
73.3M
Exchange
NMS
Currency
USD
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (25.1M) | (34.3M) | (27.8M) | (37.2M) |
| Net Income | (20.1M) | (29.7M) | (23.6M) | (32.5M) |
| Diluted EPS | $-0.32 | $-0.48 | $-0.38 | $-0.49 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (38.8M) | (83.5M) | (104.6M) | (119.7M) |
| Net Income | (37.7M) | (71.6M) | (89.0M) | (103.7M) |
| Diluted EPS | $-0.92 | $-2.01 | $-1.89 | N/A |